Levilimab

Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid[1].

Product Specifications

CAS Number

2035008-70-7

Product Name Alternative

BCD-089

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/levilimab.html

Purity

98.82

Solubility

10 mM in DMSO

Smiles

[Levilimab]

Molecular Weight

(145.7 kDa)

References & Citations

[1]Pum A, et al. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. Biomolecules. 2021 Jan 12;11 (1) :91.